Semaglutide dose escalation: what the schedule really means for you

The myth: a lower dose means the medicine isn't working yet

This is probably the most common misunderstanding our prescribers hear. People start Wegovy at 0.25mg, step to 0.5mg, and wonder when the 'real' treatment begins. The answer is that the starter steps are doing something real, they're letting your gut and your brain adjust to a GLP-1 receptor agonist before the dose reaches levels that produce meaningful appetite suppression.

Semaglutide slows gastric emptying and acts on hunger-signalling pathways. At low doses, the effect on appetite is mild; the body is simply getting used to the mechanism. Going straight to 1mg or above would, for most people, trigger far more severe nausea and vomiting than necessary. The low start isn't a warm-up in the cosmetic sense, it's a clinically rational reduction in avoidable side effects. Understanding the full range of semaglutide doses helps put each individual step in context.

So if you're three weeks into your first pen and your appetite feels broadly unchanged, that's expected. The prescriber reviewing your next dose will be looking at tolerability, not just the scale.

How the Wegovy escalation schedule actually runs

The approved UK pathway for Wegovy injection runs: 0.25mg for four weeks, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg as the standard maintenance dose, each step separated by roughly four weeks. The MHRA approved an additional step in early 2026: a 7.2mg maintenance option, initially as three 2.4mg pens per week and later as a single dedicated pen approved in April 2026 for adults with a BMI of 30 or above. That higher dose is described in more detail on the Wegovy doses overview.

Four weeks between steps isn't arbitrary. It's the time most people need to reach a steady concentration of the medicine and to find out whether a dose is genuinely tolerable day to day, not just for the first few days after injection. How the weekly injection fits into daily life is worth reading alongside the schedule.

One practical note worth mentioning: a lot of people book their first consultation around payday or at the start of a new month. That timing works fine, the consultation happens the same day and the step-up decisions happen when you come back, not before you've had a chance to try the current dose.

Your prescriber may slow the escalation if side effects are significant or speed isn't clinically indicated. Dose increases are not automatic. At nume, every repeat order goes through a fresh clinical review before any step up is confirmed, a prescriber reads your update, not a form-processing system.

Side effects at each dose step, and when to speak to someone

The semaglutide dosing page covers the full side-effect picture, but it's worth being specific about escalation here. The side effects most people notice (nausea, loose stools, reduced appetite to the point of skipping meals, occasional dizziness) tend to be at their most noticeable in the first week or two after each dose increase. They usually settle before the next step is due. This pattern repeats at each rung of the schedule, including when you reach the semaglutide 2 mg dose, which sits just below the standard 2.4mg maintenance level and can feel like a significant jump for some people.

That's the typical experience. Less commonly, vomiting can be persistent enough to cause real dehydration. If you're unable to keep fluids down, that warrants a call to a healthcare professional the same day, not a wait-and-see approach. The MHRA's Yellow Card scheme is also there for any side effect that concerns you, your report genuinely contributes to ongoing safety monitoring for this class of medicine.

Pancreatitis is a rarer but more serious risk. Severe stomach pain that feels as though it reaches into your back, with or without vomiting, should prompt urgent medical attention. The MHRA issued a Drug Safety Update in January 2026 specifically addressing this risk for GLP-1 medicines, mention it to A&E staff if you attend.

What good escalation support looks like, and what to ask for

Dose escalation is a clinical process, not a countdown. The prescriber's job at each review is to weigh up whether the current dose was genuinely tolerable, whether progress is reasonable, and whether continuing to the next step is appropriate for you specifically. That conversation should be two-way. If you found the last dose particularly difficult, say so. If you're keen to try the higher option, that's worth raising too.

The NHS semaglutide page covers what to expect in straightforward terms, and it's a good reference to read before your first dose-review conversation. It describes the standard schedule and flagged symptoms in language designed for patients rather than clinicians.

Private prescribing routes (like buying Wegovy through a regulated online pharmacy) work within the same clinical framework. The schedule doesn't change because it's private. What changes is the waiting time and the access point. If you're weighing your options, the weight-loss treatment consultation page explains how the process works at nume and what a prescriber will want to know at the outset.

Getting the escalation right matters more than getting to the next dose quickly. That's the honest answer, and it's the one our clinical team would give anyone asking.